Ziyi Wang
机构:Harbin University of Science and Technology, Shenyang Pharmaceutical University, Hebei Medical University, Xuzhou University of Technology, Academy of Medical Sciences, National Institute for Parasitic Diseases, Hohai University, Chinese University of Hong Kong, Shanghai Jiao Tong University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking University, Ministry of Ecology and Environment, Sichuan University, Fudan University, Chang'an University, China-Japan Friendship Hospital, Peking Union Medical College Hospital, Chengdu University of Technology, West China Hospital of Sichuan University, Ministry of Agriculture, Second Hospital of Hebei Medical University, Hunan Cancer Hospital, Peking University People's Hospital, Zhongshan Hospital, Vector (United States), Shanghai Sixth People's Hospital, Changzhou No.2 People's Hospital, Jiangsu Province Hospital, Hospital for Tropical Diseases, ARC Centre of Excellence for Plant Success in Nature and Agriculture, Huashan Hospital, Institute for Forecasting of the Slovak Academy of Sciences, Hubei Normal University, Tianjin Medical University, Nanjing Medical University, Shangqiu Normal University · ORCID:0000-0002-4681-6588
发表论文 123 篇 · 总被引 1942 次 · h-index 23
代表论文
- Optimization in strength-ductility of soft plate rolled AZ31 magnesium alloy via CDRX and shear band-induced DRX (2025 · Journal of Alloys and Compounds · 被引 16)
- CXCL6 Reshapes Lipid Metabolism and Induces Neutrophil Extracellular Trap Formation in Cholangiocarcinoma Progression and Immunotherapy Resistance (2025 · Advanced Science · 被引 13)
- From asphalt molecular evolution to performance degradation: Understanding aging mechanisms, inhibition strategies, and rejuvenation techniques (2025 · Fuel · 被引 12)
- Macrophages Atp6v0d2 regulates XBP1-mediated cholesterol metabolism to suppress metabolic dysfunction-associated steatohepatitis progression (2025 · International Immunopharmacology · 被引 6)
- A novel nonaerated passive constructed wetland for high-efficiency nitrogen and phosphorus removal based on slow-release oxygen regulation (2025 · Journal of environmental chemical engineering · 被引 4)
- A phase II efficacy and safety study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer. (2025 · Journal of Clinical Oncology · 被引 4)